Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Machine Learning-Powered Blood Test Estimates Age-Related Disease Risk

By LabMedica International staff writers
Posted on 23 Aug 2024

Age is a significant factor for many common chronic diseases, yet it does not perfectly represent the actual biological aging processes that drive multimorbidity and mortality. More...

Biological aging can be more accurately assessed by using 'omics data, which reflects an individual's biological functions relative to their chronological age. Traditionally, biological aging clocks have relied on DNA methylation, but protein levels might offer deeper insights into the mechanisms of aging. Researchers have now created a machine learning-based blood test that evaluates over 200 proteins to determine a person’s biological aging rate. This test is designed to predict the risk of developing 18 major age-related diseases and the likelihood of premature death.

The machine learning model that uses blood proteomic information to estimate a proteomic age clock was developed by researchers at Massachusetts General Hospital (Boston, MA, USA) in a large sample of participants from the UK Biobank. Its validity was further confirmed through tests with 3,977 participants from the China Kadoorie Biobank and 1,990 from FinnGen in Finland, covering a broad age range and various health backgrounds. This test identified 204 proteins that precisely predict chronological age, including 20 key proteins linked to aging, capturing 91% of the predictive accuracy of the larger model.

The proteomic age clock demonstrated consistent accuracy across different populations from China and Finland, matching its performance in the UK Biobank. The study, published in Nature Medicine, showed that faster proteomic aging correlates with higher risks of chronic diseases such as heart, liver, and lung diseases, diabetes, Alzheimer’s, and cancer. It also relates to overall risk of multimorbidity and mortality. Moreover, proteomic aging corresponds with biological, physical, and cognitive functions, including telomere length, frailty, and cognitive performance.

This research confirms the potential of using the proteome as a reliable indicator of biological age and functioning. It enhances understanding of the biological pathways involved in aging and disease, aids in the development of treatments, and evaluates their efficacy. Although currently used only in research settings, efforts are underway to make this test available for clinical use, enabling it to be ordered in a doctor’s office.

“Multimorbidity is an important problem in clinical and population health that has a major impact on the cost of health care. Our proteomic clock gives us a first insight into the pathways that form the biological basis for multimorbidity,” said Austin Argentieri, HMS research fellow in medicine in the Analytic and Translational Genetics Unit at Massachusetts General Hospital, who is lead author of the study. “In the near future, proteomic age clocks can be used to study the relationship between genetics and environment in aging, yielding novel insights into the drivers of aging and multimorbidity across the life span. An important avenue will also be to use proteomic clocks as a biomarker for the effectiveness of preventive interventions targeting aging and multimorbidity.”

Related Links:
Massachusetts General Hospital


New
Gold Member
Hematology Analyzer
Medonic M32B
Collection and Transport System
PurSafe Plus®
New
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
New
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.